Last reviewed · How we verify
Pneumococcal vaccine GSK1024850A
This pneumococcal conjugate vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae bacteria.
This pneumococcal conjugate vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae bacteria. Used for Prevention of invasive pneumococcal disease in adults, Prevention of pneumococcal pneumonia in adults.
At a glance
| Generic name | Pneumococcal vaccine GSK1024850A |
|---|---|
| Also known as | Synflorix |
| Sponsor | GlaxoSmithKline |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
GSK1024850A is a polysaccharide conjugate vaccine that presents pneumococcal capsular polysaccharides conjugated to a carrier protein, enabling T-cell dependent immune responses. This approach generates both antibody and cellular immunity against the targeted pneumococcal serotypes, providing protection against invasive pneumococcal disease and pneumococcal pneumonia.
Approved indications
- Prevention of invasive pneumococcal disease in adults
- Prevention of pneumococcal pneumonia in adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage
- Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A (PHASE3)
- Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease (PHASE3)
- Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination (PHASE2)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age (PHASE3)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age (PHASE3)
- Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants. (PHASE3)
- Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal vaccine GSK1024850A CI brief — competitive landscape report
- Pneumococcal vaccine GSK1024850A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI